title: Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
abstract: A soluble form of endoglin (sEng) is known to be an extracellular domain of the full-length membrane endoglin, which is elevated during various pathological conditions related to vascular endothelium. In the current review, we tried to summarize a possible role of soluble endoglin in cardiovascular pathologies, focusing on its relation to endothelial dysfunction and cholesterol levels. We discussed sEng as a proposed biomarker of cardiovascular disease progression, cardiovascular disease treatment and endothelial dysfunction. We also addressed a potential interaction of sEng with TGF-β/eNOS or BMP-9 signaling. We suggest soluble endoglin levels to be monitored, because they reflect the progression/treatment efficacy of cardiovascular diseases related to endothelial dysfunction and hypercholesterolemia. A possible role of soluble endoglin as an inducer of endothelial dysfunction however remains to be elucidated.
authors.affiliation: Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Heyrovskeho 1203, Hradec Kralove 500 05, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Rathouska
authors.affiliation: Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Heyrovskeho 1203, Hradec Kralove 500 05, Czech Republic.
authors.forename: Katerina
authors.initials: K
authors.lastname: Jezkova
authors.affiliation: Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Heyrovskeho 1203, Hradec Kralove 500 05, Czech Republic.
authors.forename: Ivana
authors.initials: I
authors.lastname: Nemeckova
authors.affiliation: Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Heyrovskeho 1203, Hradec Kralove 500 05, Czech Republic. Electronic address: nachti@faf.cuni.cz.
authors.forename: Petr
authors.initials: P
authors.lastname: Nachtigal
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000071063:Endoglin; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000503:physiopathology; D055427:Growth Differentiation Factor 2; D055412:Growth Differentiation Factors / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000097:blood*; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; C064206:ENG protein, human; D000071063:Endoglin; C525887:GDF2 protein, human; D055427:Growth Differentiation Factor 2; D055412:Growth Differentiation Factors; D011956:Receptors, Cell Surface; D016212:Transforming Growth Factor beta; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III
keywords: Endothelial dysfunction; Hypercholesterolemia; Soluble endoglin